US Pharmacopeia has entered into a research collaboration focused on inflammation with Celgene Corporation. The companies will work together to identify promising small molecule lead compounds suitable for further development.
Under the terms of this agreement, Pharmacopeia will provide its small molecule discovery expertise in identifying leads against a selected Celgene target. Pharmacopeia will receive funding for providing these research activities and will be entitled to receive additional payments upon the successful achievement of milestones and royalties upon the commercialisation of any drugs emanating from this relationship.
"We were very pleased when the opportunity arose to combine our expertise in the kinase arena with Celgene's own considerable experience to work on one of their proprietary kinases," said Joseph A. Mollica, chairman, president & CEO of Pharmacopeia. "We look forward to working together and to a successful program," he added.
"Celgene has developed an extensive pipeline of novel kinase inhibitors that have demonstrated activity in preclinical disease models and are now progressing into the development phase," said Alan J. Lewis, president of Celgene's San Diego Research Division. "We expect this collaboration to further expand our kinase inhibitor portfolio for the treatment of inflammatory diseases and cancer."